Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays

QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2007-11, Vol.42 (11), p.1370-1381
Hauptverfasser: Casañola-Martín, Gerardo M., Marrero-Ponce, Yovani, Khan, Mahmud Tareq Hassan, Ather, Arjumand, Khan, Khalid M., Torrens, Francisco, Rotondo, Richard
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1381
container_issue 11
container_start_page 1370
container_title European journal of medicinal chemistry
container_volume 42
creator Casañola-Martín, Gerardo M.
Marrero-Ponce, Yovani
Khan, Mahmud Tareq Hassan
Ather, Arjumand
Khan, Khalid M.
Torrens, Francisco
Rotondo, Richard
description QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class = − 96.067 + 1.988 × 10 2 X0Av + 91.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The biosilico assays and in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound BP4 (IC 50 = 1.72 μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC 50 = 16.67 μM) and l-mimosine (IC 50 = 3.68 μM). These results support the role of biosilico algorithm for the identification of new tyrosinase inhibitor compounds. [Display omitted]
doi_str_mv 10.1016/j.ejmech.2007.01.026
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68543190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523407000773</els_id><sourcerecordid>68543190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo7rj6D0Ry0Vu3SSfp7ngQ1vUTFrzoOaTTlZ0aupMxyQzOvzfLDOzNU0HxvC9VDyGvOWs54_37XQu7Fdy27RgbWsZb1vVPyIYP_diITsmnZMO6TjSqE_KKvMh5xxhTPWPPyVWFxCDHfkP2n5O9j4GuULZxpj4m6jHMGO5piEdYaDmlmDHYDBTDFicsMeUP9BPW7YIuUpwhFPTobMFaZMNM4e8eEq51b5eaokcsKVKbsz3ll-SZt0uGV5d5TX5__fLr9ntz9_Pbj9ubu8YJzUrTjcICCCaVlgL0xPteSS4H7TxXk1NSeuv44LiVetS-10xCNzk9T35Wig_imrw79-5T_HOAXMyK2cGy2ADxkE0_Kim4ZhWUZ9DVR3MCb_b1dptOhjPzYNrszNm0eTBtGDfVdI29ufQfphXmx9BFbQXeXgCbnV18ssFhfuT0OErOZeU-njmoNo4IyWSHEBzMmMAVM0f8_yX_AHL-n_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68543190</pqid></control><display><type>article</type><title>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Casañola-Martín, Gerardo M. ; Marrero-Ponce, Yovani ; Khan, Mahmud Tareq Hassan ; Ather, Arjumand ; Khan, Khalid M. ; Torrens, Francisco ; Rotondo, Richard</creator><creatorcontrib>Casañola-Martín, Gerardo M. ; Marrero-Ponce, Yovani ; Khan, Mahmud Tareq Hassan ; Ather, Arjumand ; Khan, Khalid M. ; Torrens, Francisco ; Rotondo, Richard</creatorcontrib><description>QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class = − 96.067 + 1.988 × 10 2 X0Av + 91.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The biosilico assays and in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound BP4 (IC 50 = 1.72 μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC 50 = 16.67 μM) and l-mimosine (IC 50 = 3.68 μM). These results support the role of biosilico algorithm for the identification of new tyrosinase inhibitor compounds. [Display omitted]</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2007.01.026</identifier><identifier>PMID: 17637486</identifier><identifier>CODEN: EJMCA5</identifier><language>eng</language><publisher>Oxford: Elsevier Masson SAS</publisher><subject>Biological and medical sciences ; Bipiperidine series ; Computational Biology ; Computer Simulation ; Databases, Factual ; Discriminant Analysis ; Dragon descriptor ; Drug Design ; LDA-based QSAR model ; Ligands ; Medical sciences ; Peptides - analysis ; Peptides - chemistry ; Peptides - classification ; Peptides - pharmacology ; Pharmacology. Drug treatments ; Piperidines - chemistry ; Piperidines - pharmacology ; Quantitative Structure-Activity Relationship ; Reproducibility of Results ; Skin, nail, hair, dermoskeleton ; Software ; Tyrosinase inhibitor ; Virtual screening</subject><ispartof>European journal of medicinal chemistry, 2007-11, Vol.42 (11), p.1370-1381</ispartof><rights>2007 Elsevier Masson SAS</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</citedby><cites>FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2007.01.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19884114$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17637486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casañola-Martín, Gerardo M.</creatorcontrib><creatorcontrib>Marrero-Ponce, Yovani</creatorcontrib><creatorcontrib>Khan, Mahmud Tareq Hassan</creatorcontrib><creatorcontrib>Ather, Arjumand</creatorcontrib><creatorcontrib>Khan, Khalid M.</creatorcontrib><creatorcontrib>Torrens, Francisco</creatorcontrib><creatorcontrib>Rotondo, Richard</creatorcontrib><title>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class = − 96.067 + 1.988 × 10 2 X0Av + 91.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The biosilico assays and in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound BP4 (IC 50 = 1.72 μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC 50 = 16.67 μM) and l-mimosine (IC 50 = 3.68 μM). These results support the role of biosilico algorithm for the identification of new tyrosinase inhibitor compounds. [Display omitted]</description><subject>Biological and medical sciences</subject><subject>Bipiperidine series</subject><subject>Computational Biology</subject><subject>Computer Simulation</subject><subject>Databases, Factual</subject><subject>Discriminant Analysis</subject><subject>Dragon descriptor</subject><subject>Drug Design</subject><subject>LDA-based QSAR model</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Peptides - analysis</subject><subject>Peptides - chemistry</subject><subject>Peptides - classification</subject><subject>Peptides - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - chemistry</subject><subject>Piperidines - pharmacology</subject><subject>Quantitative Structure-Activity Relationship</subject><subject>Reproducibility of Results</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Software</subject><subject>Tyrosinase inhibitor</subject><subject>Virtual screening</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoMo7rj6D0Ry0Vu3SSfp7ngQ1vUTFrzoOaTTlZ0aupMxyQzOvzfLDOzNU0HxvC9VDyGvOWs54_37XQu7Fdy27RgbWsZb1vVPyIYP_diITsmnZMO6TjSqE_KKvMh5xxhTPWPPyVWFxCDHfkP2n5O9j4GuULZxpj4m6jHMGO5piEdYaDmlmDHYDBTDFicsMeUP9BPW7YIuUpwhFPTobMFaZMNM4e8eEq51b5eaokcsKVKbsz3ll-SZt0uGV5d5TX5__fLr9ntz9_Pbj9ubu8YJzUrTjcICCCaVlgL0xPteSS4H7TxXk1NSeuv44LiVetS-10xCNzk9T35Wig_imrw79-5T_HOAXMyK2cGy2ADxkE0_Kim4ZhWUZ9DVR3MCb_b1dptOhjPzYNrszNm0eTBtGDfVdI29ufQfphXmx9BFbQXeXgCbnV18ssFhfuT0OErOZeU-njmoNo4IyWSHEBzMmMAVM0f8_yX_AHL-n_I</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Casañola-Martín, Gerardo M.</creator><creator>Marrero-Ponce, Yovani</creator><creator>Khan, Mahmud Tareq Hassan</creator><creator>Ather, Arjumand</creator><creator>Khan, Khalid M.</creator><creator>Torrens, Francisco</creator><creator>Rotondo, Richard</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</title><author>Casañola-Martín, Gerardo M. ; Marrero-Ponce, Yovani ; Khan, Mahmud Tareq Hassan ; Ather, Arjumand ; Khan, Khalid M. ; Torrens, Francisco ; Rotondo, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Bipiperidine series</topic><topic>Computational Biology</topic><topic>Computer Simulation</topic><topic>Databases, Factual</topic><topic>Discriminant Analysis</topic><topic>Dragon descriptor</topic><topic>Drug Design</topic><topic>LDA-based QSAR model</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Peptides - analysis</topic><topic>Peptides - chemistry</topic><topic>Peptides - classification</topic><topic>Peptides - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - chemistry</topic><topic>Piperidines - pharmacology</topic><topic>Quantitative Structure-Activity Relationship</topic><topic>Reproducibility of Results</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Software</topic><topic>Tyrosinase inhibitor</topic><topic>Virtual screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casañola-Martín, Gerardo M.</creatorcontrib><creatorcontrib>Marrero-Ponce, Yovani</creatorcontrib><creatorcontrib>Khan, Mahmud Tareq Hassan</creatorcontrib><creatorcontrib>Ather, Arjumand</creatorcontrib><creatorcontrib>Khan, Khalid M.</creatorcontrib><creatorcontrib>Torrens, Francisco</creatorcontrib><creatorcontrib>Rotondo, Richard</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casañola-Martín, Gerardo M.</au><au>Marrero-Ponce, Yovani</au><au>Khan, Mahmud Tareq Hassan</au><au>Ather, Arjumand</au><au>Khan, Khalid M.</au><au>Torrens, Francisco</au><au>Rotondo, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>42</volume><issue>11</issue><spage>1370</spage><epage>1381</epage><pages>1370-1381</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><coden>EJMCA5</coden><abstract>QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class = − 96.067 + 1.988 × 10 2 X0Av + 91.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The biosilico assays and in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound BP4 (IC 50 = 1.72 μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC 50 = 16.67 μM) and l-mimosine (IC 50 = 3.68 μM). These results support the role of biosilico algorithm for the identification of new tyrosinase inhibitor compounds. [Display omitted]</abstract><cop>Oxford</cop><pub>Elsevier Masson SAS</pub><pmid>17637486</pmid><doi>10.1016/j.ejmech.2007.01.026</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2007-11, Vol.42 (11), p.1370-1381
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_68543190
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Biological and medical sciences
Bipiperidine series
Computational Biology
Computer Simulation
Databases, Factual
Discriminant Analysis
Dragon descriptor
Drug Design
LDA-based QSAR model
Ligands
Medical sciences
Peptides - analysis
Peptides - chemistry
Peptides - classification
Peptides - pharmacology
Pharmacology. Drug treatments
Piperidines - chemistry
Piperidines - pharmacology
Quantitative Structure-Activity Relationship
Reproducibility of Results
Skin, nail, hair, dermoskeleton
Software
Tyrosinase inhibitor
Virtual screening
title Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A50%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dragon%20method%20for%20finding%20novel%20tyrosinase%20inhibitors:%20Biosilico%20identification%20and%20experimental%20in%20vitro%20assays&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Casa%C3%B1ola-Mart%C3%ADn,%20Gerardo%20M.&rft.date=2007-11-01&rft.volume=42&rft.issue=11&rft.spage=1370&rft.epage=1381&rft.pages=1370-1381&rft.issn=0223-5234&rft.eissn=1768-3254&rft.coden=EJMCA5&rft_id=info:doi/10.1016/j.ejmech.2007.01.026&rft_dat=%3Cproquest_cross%3E68543190%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68543190&rft_id=info:pmid/17637486&rft_els_id=S0223523407000773&rfr_iscdi=true